News Image

Why the dividend investor may take a look at NASDAQ:AMGN.

By Mill Chart

Last update: Feb 12, 2024

Our stock screener has singled out AMGEN INC (NASDAQ:AMGN) as a promising choice for dividend investors. NASDAQ:AMGN not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.

Dividend Assessment of NASDAQ:AMGN

An integral part of ChartMill's stock analysis is the Dividend Rating, which spans from 0 to 10. This rating evaluates diverse dividend factors, including yield, historical data, growth, and sustainability. NASDAQ:AMGN has received a 7 out of 10:

  • AMGN's Dividend Yield is rather good when compared to the industry average which is at 14.12. AMGN pays more dividend than 98.65% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.50, AMGN pays a bit more dividend than the S&P500 average.
  • On average, the dividend of AMGN grows each year by 10.76%, which is quite nice.
  • AMGN has been paying a dividend for at least 10 years, so it has a reliable track record.
  • AMGN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

A Closer Look at Health for NASDAQ:AMGN

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:AMGN was assigned a score of 5 for health:

  • With a decent Altman-Z score value of 1.79, AMGN is doing good in the industry, outperforming 65.82% of the companies in the same industry.
  • With an excellent Debt to FCF ratio value of 6.45, AMGN belongs to the best of the industry, outperforming 94.59% of the companies in the same industry.
  • AMGN has a Current Ratio of 2.86. This indicates that AMGN is financially healthy and has no problem in meeting its short term obligations.
  • AMGN has a Quick Ratio of 2.56. This indicates that AMGN is financially healthy and has no problem in meeting its short term obligations.

Evaluating Profitability: NASDAQ:AMGN

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:AMGN was assigned a score of 7 for profitability:

  • Looking at the Return On Assets, with a value of 8.36%, AMGN belongs to the top of the industry, outperforming 96.95% of the companies in the same industry.
  • With an excellent Return On Equity value of 98.82%, AMGN belongs to the best of the industry, outperforming 99.83% of the companies in the same industry.
  • AMGN has a Return On Invested Capital of 10.82%. This is amongst the best in the industry. AMGN outperforms 96.45% of its industry peers.
  • The last Return On Invested Capital (10.82%) for AMGN is well below the 3 year average (14.92%), which needs to be investigated, but indicates that AMGN had better years and this may not be a problem.
  • AMGN has a Profit Margin of 28.20%. This is amongst the best in the industry. AMGN outperforms 98.14% of its industry peers.
  • Looking at the Operating Margin, with a value of 33.95%, AMGN belongs to the top of the industry, outperforming 98.14% of the companies in the same industry.
  • AMGN has a better Gross Margin (73.74%) than 83.93% of its industry peers.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

Check the latest full fundamental report of AMGN for a complete fundamental analysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

AMGEN INC

NASDAQ:AMGN (4/26/2024, 7:00:00 PM)

After market: 270.3 +0.32 (+0.12%)

269.98

+0.6 (+0.22%)

AMGN News

News Image2 days ago - AmgenAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency...

News Image5 days ago - The Motley FoolBetter Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

News Image5 days ago - The Motley Fool1 No-Brainer Vanguard Fund to Buy Right Now

This Vanguard growth fund is home to some of the world's most innovative companies.

News Image9 days ago - InvestorPlaceThe Dividend Goldmine: 3 Shining Stocks With Growing Payouts

Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns.

News Image10 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Amgen
News Image11 days ago - Market News VideoNoteworthy Wednesday Option Activity: UPS, AMGN, BMEA
News Image11 days ago - InvestorPlaceSell These 3 Blue-Chip Stocks Before the Next Earnings Stumble

Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell.

News Image11 days ago - InvestorPlaceComing FDA Approvals Could Send These 3 Drug Stocks Soaring

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.

News Image11 days ago - The Motley FoolCan This High-Yield Dividend Stock Keep Beating the S&P 500?

Amgen's shares have come under pressure this year, making it a compelling bargain buy.

News Image11 days ago - The Motley FoolGot $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever

Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.

News Image12 days ago - AmgenAMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic...

News Image12 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy Now: Q2 Edition

Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.

AMGN Links
Follow us for more